Back to Stakeholders

Federal University of São Paulo (UNIFESP)

CategoriesUniversities and Colleges without Dedicated Psychedelic Research GroupsResearch, Drug Development & Manufacturing

Data updated

3 Trials1 Paper

The Federal University of São Paulo (UNIFESP) is a public federal research university based in the state of São Paulo, Brazil, with multiple campuses and a strong reputation in health sciences and related programs.

Academic Research

1 papers

Published Papers

1

Trial Involvement

3

Distinct Focus Topics

0

Latest Publication

Feb 1, 2018

Recent Papers

Research journey

Federal University of São Paulo (UNIFESP) works on Ayahuasca. Here is where that compound’s research stands.

Research journey

16 trials · 250 papers

Full timeline →

Tap any milestone for detail. 1851 to 2025.

Featured in topic journeys

Clinical research timelines that include a curated milestone from Federal University of São Paulo (UNIFESP).

Alcohol Use Disorder (AUD)Substance Use Disorders (SUD)

Quick Facts

Website
Visit

Sponsored Trials

1
Not yet recruitingIII

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

Start Date
Compounds
Ketamine, Placebo

Where this pipeline sits in the field

Federal University of São Paulo (UNIFESP) runs late-stage trials that Blossom ranks by how soon a catalyst is expected, alongside every other Phase 2 and Phase 3 study in the field.

Open the forecast →

Collaborated Trials

2
CompletedII

Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

Start Date
Compounds
Ibogaine
CompletedI, II

Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

Start Date
Compounds
Ayahuasca, Placebo

Research Papers

1
Open AccessindividualLong-term follow-up

Longterm effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up

This qualitative follow-up study (n=8) interviewed patients 4-7 years after the intake of ayahuasca (123.2 mg DMT, 32.34mg Harmine) within the context of a previous open-label study; most patients reported that the experience was among the most important of their lives, but no long-term improvements in depression scores (MADRS) were found.

Published
Journal
Archives of Clinical Psychiatry (São Paulo)
Authors
Dos Santos, R. G., Osório, F. L., Hallak, J. E.

Recent activity